{"id":33943,"date":"2025-05-22T22:12:08","date_gmt":"2025-05-22T14:12:08","guid":{"rendered":"https:\/\/flcube.com\/?p=33943"},"modified":"2025-05-22T22:12:09","modified_gmt":"2025-05-22T14:12:09","slug":"shanghai-int-medical-instruments-to-acquire-majority-stake-in-endonom-medical","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33943","title":{"rendered":"Shanghai INT Medical Instruments to Acquire Majority Stake in Endonom Medical"},"content":{"rendered":"\n

China-based Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501<\/a>) is set to jointly acquire a total of 81.83% stakes in compatriot firm Endonom Medical (Hangzhou) with Shanghai Chenyue Weixin Medical Technology Co., Ltd for RMB 512.84 million (USD 71.2 million). INT Med will obtain a 51.7% stake in Endonom Med for RMB 324 million (USD 45 million).<\/p>\n\n\n\n

Company Profiles<\/strong>
INT Med is a leading manufacturer of intracardiac interventional devices in China, known for its innovative solutions in the medical device industry. Endonom Med specializes in the research, development, manufacturing, and sales of peripheral vascular intervention medical devices, contributing to advancements in vascular health. Chenyue Weixin, a corporate management consulting firm, is ultimately owned by the Shanghai State-owned Assets Supervision and Administration Commission, providing strategic oversight and support.<\/p>\n\n\n\n

Strategic Implications<\/strong>
This acquisition represents a strategic move for INT Med to expand its footprint in the vascular intervention market, leveraging Endonom Med’s expertise and product offerings. The collaboration with Chenyue Weixin further strengthens the acquisition, aligning with broader state-owned enterprise objectives to enhance healthcare capabilities and innovation.-Fineline Info & Tech<\/a><\/p>\n\n\n\n